Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Dosage
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Dosage

2 evidence topics · 2 sources

Dosing: EMBOLD protocol

“0.5 mg/kg/day PRAX-562 QD” (opens the source at this quote in a new tab)
“Dose adjustment is permitted to a maximum of 1.0 mg/kg/day and a minimum of 0.25 mg/kg/day.” (opens the source at this quote in a new tab)

Dosing: manufacturer presentation

“No titration required” (opens the source at this quote in a new tab)
“Once daily dosing” (opens the source at this quote in a new tab)